Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections present with
increased disease severity and poor clinical outcomes in diabetic patients compared with …

Coronavirus Disease 2019 (COVID-19), caused by a new strain of coronavirus called
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared a …

Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-
19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects …

It is a lesser-known fact that metformin was originally introduced as an anti-influenza drug
and that glucose-lowering was only one of its side effects [1]. The many pleiotropic effects of …

The current outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2) infection has spread across the world. No specific antiviral agents have been adequately …

Introduction Diabetes mellitus (DM) is one of the most common comorbidities among
patients with coronavirus disease 2019 (COVID-19) which may exacerbate complications of …

The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial
impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and …

Most of the expert consensus to date have suggested avoiding metformin in patients with
diabetes and coronavirus disease-19 (COVID-19), due to an anticipated fear of lactic …

Metformin is the first-line medication for type 2 diabetes, but it also has a long history of
improved outcomes in infectious diseases, such as influenza, hepatitis C, and in-vitro assays …

Type 2 diabetes mellitus (T2DM) is associated with both poorer clinical outcomes during the
COVID-19 pandemic and an increased risk of death in such hospitalized patients. While the …